Table 4. The associations between the MT-2A rs28366003 polymorphism and clinical characteristics of BC patients.
| Variable | GG(%) | GC(%) | p | OR(95%CI) | CC(%) | p | OR(95%CI) | GC+CC (%) | p | OR(95%CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| Tumor size | ||||||||||
| <2CM | 57(37.5) | 54(35.5) | 41(27) | 95(62.5) | ||||||
| ≥2CM | 98(31.9) | 104(33.9) | 0.63 | 1.12(0.71-1.78) | 105(34.2) | 0.11 | 1.49(0.92-2.42) | 209(68.1) | 0.23 | 1.14(0.74-1.75) |
| LN metastasis | ||||||||||
| Negative | 45(24.5) | 56(30.4) | 83(45.1) | 139(75.5) | ||||||
| Positive | 67(24.4) | 78(28.4) | 0.8 | 0.94(0.56-1.56) | 130(47.3) | 0.83 | 1.05 (0.66-1.68 ) | 208(75.6) | 0.98 | 1.01(0.65-1.55) |
| ER | ||||||||||
| Negative | 70(34.7) | 65(32.2) | 67(33.2) | 132(65.3) | ||||||
| Positive | 69(26.8) | 88(34.2) | 0.18 | 1.37(0.87-2.18) | 100(39) | 0.07 | 1.51 (0.96-2.39 ) | 188(73.2) | 0.07 | 1.44(0.97-2.16) |
| PR | ||||||||||
| Negative | 55(26.4) | 67(32.2) | 86(41.3) | 153(73.6) | ||||||
| Positive | 77(30.7) | 81(32.2) | 0.54 | 0.86(0.54-1.39 ) | 93(37.1) | 0.26 | 0.77(0.49-1.22) | 174(69.3) | 0.32 | 0.81 (0.54-1.22) |
| Her-2 | ||||||||||
| Negative | 71(21.5) | 82(24.8) | 177(53.6) | 259(78.5) | ||||||
| Positive | 35(27.1) | 33(25.6) | 0.49 | 0.82(0.46-1.45) | 61(47.3) | 0.16 | 0.7(0.43-1.15) | 94(72.9) | 0.2 | 0.74(0.46-1.18) |
| Ki-67 | ||||||||||
| <14% | 44(145) | 105(35.7) | 145(49.3) | 250(85) | ||||||
| ≥14% | 27(16.3) | 64(38.8) | 0.98 | 0.99(0.56-1.76) | 74(44.8) | 0.52 | 0.83(0.48-1.45) | 138(83.6) | 0.69 | 0.9(0.53-1.52) |
| Histological grade | ||||||||||
| SBR 1-2 | 49(20) | 34(13.9) | 161(66) | 195(79.9) | ||||||
| SBR 3 | 57(26.5) | 61(28.4) | 0.13 | 1.54(0.88-2.72) | 97(45.1) | 0.005 | 0.52(0.33-0.82) | 158(73.5) | 0.1 | 0.79(0.45-1.08) |
| Venous Invasion | ||||||||||
| None-little | 94(32.2) | 102(34.9) | 96(32.9) | 198(67.8) | ||||||
| Moderate-severe | 51(30.5) | 57(34.1) | 0.9 | 1.03(0.64-1.65) | 59(35.3) | 0.6 | 1.1(0.71-1.81) | 116(69.5) | 0.71 | 1.08(0.72-1.63) |
LN: Axillary lymph node; ER: Estrogen receptor; PR: Progesterone receptor; Her-2: human epidermal growth factor receptor 2; SBR: Scarff, Bloom and Richardson tumor grade